B-type natriuretic peptide (BNP) is the first biomarker of proven value in screening for left ventricular dysfunction. The availability of point-of-care testing has escalated clinical interest and the resultant research is defining a role for BNP in the investigation and treatment of critically ill patients.
This review was undertaken with the aim of collecting and assimilating current evidence regarding the use of BNP assay in the evaluation of myocardial dysfunction in critically ill humans. The information is presented in a format based upon organ system and disease category.
BNP assay has been studied in a spectrum of clinical conditions ranging from acute dyspnoea to subarachnoid haemorrhage. Its role in diagnosis, assessment of disease severity, risk stratification and prognostic evaluation of cardiac dysfunction appears promising, but requires further elaboration. The heterogeneity of the critically ill population appears to warrant a range of cut-off values. Research addressing progressive changes in BNP concentration is hindered by infrequent assay and appears unlikely to reflect the critically inpatient's rapidly changing haemodynamics. Multi-marker strategies may prove valuable in prognostication and evaluation of therapy in a greater variety of illnesses. Scant data exist regarding the use of BNP assay to alter therapy or outcome.
It appears that BNP assay offers complementary information to conventional approaches for the evaluation of cardiac dysfunction. Continued research should augment the validity of BNP assay in the evaluation of myocardial function in patients with life-threatening illness.
KangawaK., MatsuoH.Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP).Biochem Biophys Res Commun1984; 118: 131–139.
5.
de BoldA.J., BorensteinH.B., VeressA.T., SonnenbergH.A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.Life Sci1981; 28: 89–94.
6.
SudohT., KangawaK., MinaminoN., MatsuoH.A new natriuretic peptide in porcine brain.Nature1988; 332: 78–81.
7.
YasueH., YoshimuraM., SumidaH.Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.Circulation1994; 90: 195–203.
8.
SudohT., MinaminoN., KangawaK., MatsuoH.C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain.Biochem Biophys Res Commun1990; 168: 863–870.
9.
MatsuoH.Discovery of a natriuretic peptide family and their clinical application.Can J Physiol Pharmacol2001; 79: 736–740.
10.
BaxterG.F.The natriuretic peptides.Basic Res Cardiol2004; 99: 71–75.
11.
YamamotoK., BurnettJ.C.Jr., JougasakiM.Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.Hypertension1996; 28: 988–994.
12.
MaiselA.S., McCulloughP.A.Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management.Rev Cardiovasc Med2003; 4 Suppl 4: S3–12.
13.
SawadaY., SudaM., YokoyamaH.Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin.J Biol Chem1997; 272: 20545–20554.
14.
NakaoK., MukoyamaM., HosodaK.Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide.Can J Physiol Pharmacol1991; 69: 1500–1506.
15.
HallC.Essential biochemistry and physiology of (NT-pro)BNP Eur J Heart Fail2004; 6: 257–260.
16.
NakagawaO., OgawaY., ItohH.Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload.J Clin Invest1995; 96: 1280–1287.
17.
TenhunenO., SzokodiI., RuskoahoH.Posttranscriptional activation of BNP gene expression in response to increased left ventricular wall stress: role of calcineurin and PKCRegul Pept2005; 128: 187–196.
18.
MukoyamaM., NakaoK., HosodaK.Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.J Clin Invest1991; 87: 1402–1412.
19.
OgawaY., ItohH., TamuraN.Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene.J Clin Invest1994; 93: 1911–1921.
MaackT., SuzukiM., AlmeidaF.A.Physiological role of silent receptors of atrial natriuretic factor.Science1987; 238: 675–678.
22.
Anand-SrivastavaM.B.Natriuretic peptide receptor-C signaling and regulation.Peptides2005; 26: 1044–1059.
23.
SmithM.W., EspinerE.A., YandleT.G., CharlesC.J., RichardsA.M.Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase.J Endocrinol2000; 167: 239–246.
24.
McLeanA.S., HuangS.J., NalosM., TangB., StewartD.E.The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients.Crit Care Med2003; 31: 2611–2618.
25.
EmdinM., ClericoA., ClemenzaF.Recommendations for the clinical use of cardiac natriuretic peptides.Ital Heart J2005; 6: 430–446.
26.
TroughtonR.W., RichardsA.M., YandleT.G., NichollsG.Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure.Circulation2004; 109: e325–6; author reply e-6.
27.
YancyC.W.Practical considerations for BNP use.Heart Fail Rev2003; 8: 369–373.
28.
ClericoA., EmdinM.Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review.Clin Chem2004; 50: 33–50.
29.
EpshteynV., MorrisonK., KrishnaswamyP.Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes.Diabetes Care2003; 26: 2081–2087.
30.
AsakawaH., FukuiT., TokunagaK., KawakamiF.Plasma brain natriuretic peptide levels in normotensive Type 2 diabetic patients without cardiac disease and macroalbuminuria.J Diabetes Complications2002; 16: 209–213.
31.
OhsakiY., GrossA.J., LeP.T., OieH., JohnsonB.E.Human small cell lung cancer cells produce brain natriuretic peptide.Oncology1999; 56: 155–159.
32.
WalterM., BerendesE., ClaviezA., SuttorpM.Inappropriate secretion of natriuretic peptides in a patient with a cerebral tumor.JAMA1999; 282: 27–28.
33.
WangT.J., LarsonM.G., LevyD.Impact of obesity on plasma natriuretic peptide levels.Circulation2004; 109: 594–600.
34.
NousiainenT., VanninenE., JantunenE.Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.J Intern Med2002; 251: 228–234.
35.
SnowdenJ.A., HillG.R., HuntP.Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide.Bone Marrow Transplant2000; 26: 309–313.
36.
GiannitsisE., KatusH.A.Still unresolved issues with brain-type natriuretic peptide measurement in the critically ill patient.Crit Care Med2003; 31: 2703–2704.
37.
ClericoA., PronteraC., EmdinM.Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP.Clin Chem2005; 51: 445–447.
38.
McLeanA.S., TangB., NalosM., HuangS.J., StewartD.E.Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients.Anaesth Intensive Care2003; 31: 21–27.
39.
MaiselA.B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient.Rev Cardiovasc Med2002; 3 Suppl 4: S10–17.
40.
BerendesE., Van AkenH., RaufhakeC., SchmidtC., AssmannG., WalterM.Differential secretion of atrial and brain natriuretic peptide in critically ill patients.Anesth Analg2001; 93: 676–682.
41.
TungR.H., GarciaC., MorssA.M.Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock.Crit Care Med2004; 32: 1643–1647.
42.
CuthbertsonB.H., PatelR.R., CroalB.L., BarclayJ., HillisG.S.B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care.Anaesthesia2005; 60: 16–21.
43.
DokainishH., ZoghbiW.A., LakkisN.M.Optimal non-invasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters.Circulation2004; 109: 2432–2439.
44.
de DenusS., PharandC., WilliamsonD.R.Brain natriuretic peptide in the management of heart failure: the versatile neurohormone.Chest2004; 125: 652–668.
45.
KnudsenC.W., RiisJ.S., FinsenA.V.Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender.Eur J Heart Fail2004; 6: 55–62.
46.
MaiselA.S., KrishnaswamyP., NowakR.M.Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med2002; 347: 161–167.
47.
McCulloughP.A., SandbergK.R.Sorting out the evidence on natriuretic peptides.Rev Cardiovasc Med2003; 4 Suppl 4: S13–9.
48.
PrahashA., LynchT.B-type natriuretic peptide: a diagnostic, prognostic, and therapeutic tool in heart failure.Am J Crit Care2004; 13: 46–53; quiz 4–5.
49.
TsutamotoT., WadaA., MaedaK.Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.Circulation1997; 96: 509–516.
50.
BergerR., HuelsmanM., StreckerK.B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.Circulation2002; 105: 2392–2397.
51.
ChengV., KazanagraR., GarciaA.A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.J Am Coll Cardiol2001; 37: 386–391.
52.
AnandI.S., FisherL.D., ChiangY.T.Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).Circulation2003; 107: 1278–1283.
53.
IshiiJ., NomuraM., NakamuraY.Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure.Am J Cardiol2002; 89: 691–695.
54.
FonarowG.C., HorwichT.B.Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure.Rev Cardiovasc Med2003; 4 Suppl 4: S20–28.
55.
IshiiJ., CuiW., KitagawaF.Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure.Clin Chem2003; 49: 2020–2026.
56.
SodianR., LoebeM., SchmittC.Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems.J Am Coll Cardiol2001; 38: 1942–1949.
57.
MarumotoK., HamadaM., HiwadaK.Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris.Clin Sci (Lond)1995; 88: 551–556.
58.
de LemosJ.A., MorrowD.A.Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes.Rev Cardiovasc Med2003; 4 Suppl 4: S37–46.
59.
OmlandT., AakvaagA., BonarjeeW.Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.Circulation1996; 93: 1963–1969.
60.
RichardsA.M., NichollsM.G., EspinerE.A.B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.Circulation2003; 107: 2786–2792.
61.
RichardsA.M., NichollsM.G., YandleT.G.Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group.Heart1999; 81: 114–120.
62.
ArakawaN., NakamuraM., EndoH., SugawaraS., SuzukiT., HiramoriK.Brain natriuretic peptide and cardiac rupture after acute myocardial infarction.Intern Med2001; 40: 232–236.
63.
OmlandT., de LemosJ.A., MorrowD.A.Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes.Am J Cardiol2002; 89: 463–465.
64.
MorrowD.A., de LemosJ.A., SabatineM.S.Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.J Am Coll Cardiol2003; 41: 1264–1272.
65.
TerazawaE., DohiS., AkamastsuS., OhataH., ShimonakaH.Changes in calcitonin gene-related peptide, atrial natriuretic peptide and brain natriuretic peptide in patients undergoing coronary artery bypass grafting.Anaesthesia2003; 58: 223–232.
66.
MastersR.G., DaviesR.A., VeinotJ.P., HendryP.J., SmithS.J., de BoldA.J.Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans.Circulation1999; 100: 287–291.
67.
HervasI., AlmenarL., Perez-PastorJ.L.Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection.Nucl Med Commun2003; 24: 925–931.
68.
GerberI.L., StewartR.A., FrenchJ.K.Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation.Am J Cardiol2003; 92: 755–758.
69.
FukudaN., ShinoharaH., SakabeK., NadaT., TamuraY.Plasma levels of brain natriuretic peptide in various forms of obstruction to the left ventricular outflow tract.J Heart Valve Dis2003; 12: 333–340.
70.
SuttonT.M., StewartR.A., GerberI.L.Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation.J Am Coll Cardiol2003; 41: 2280–2287.
71.
KellyC.A., NewbyD.E., McDonaghT.A.Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations.Eur Heart J2002; 23: 1379–1386.
72.
ThorensJ.B., RitzM., ReynardC.Haemodynamic and endocrinological effects of noninvasive mechanical ventilation in respiratory failure.Eur Respir J1997; 10: 2553–2559.
73.
KrugerS., GrafJ., MerxM.W.Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism.Am Heart J2004; 147: 60–65.
74.
BilkovskiR.N., KulstadE.B.Elevations of B-type natriuretic peptide in pulmonary embolism: a case series.J Emerg Med2003; 25: 415–420.
75.
KucherN., PrintzenG., GoldhaberS.Z.Prognostic role of brain natriuretic peptide in acute pulmonary embolism.Circulation2003; 107: 2545–2547.
76.
ten WoldeM., TulevskiI.I., MulderJ.W.Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism.Circulation2003; 107: 2082–2084.
77.
MitakaC., HirataY., NaguraT., TsunodaY., ItohM., AmahaK.Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury.J Crit Care1997; 12: 66–71.
78.
MaederM., AmmannP., RickliH., DiethelmM.Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome.Swiss Med Wkly2003; 133: 515–518.
79.
CharpentierJ., LuytC.E., FullaY.Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis.Crit Care Med2004; 32: 660–665.
80.
WitthautR., BuschC., FraunbergerP.Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction.Intensive Care Med2003; 29: 1696–1702.
ParekhN., VenkateshB., CrossD.Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage.J Am Coll Cardiol2000; 36: 1328–1335.
83.
BalikM., JaborA., KolarM.Relationship between natriuretic peptides and residual diuresis during continuous hemodiafiltration.Blood Purif2003; 21: 401–408.
84.
HenriksenJ.H., GotzeJ.P., FuglsangS., ChristensenE., BendtsenF., MollerS.Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.Gut2003; 52: 1511–1517.
85.
WongF., SiuS., LiuP., BlendisL.M.Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?Clin Sci (Lond)2001; 101: 621–628.
86.
BellomoR., UchinoS.Cardiovascular monitoring tools: use and misuse.Curr Opin Crit Care2003; 9: 225–229.
JensenK.T., CarstensJ., IvarsenP., PedersenE.B.A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases.Scand J Clin Lab Invest1997; 57: 529–540.
89.
KandaH., KitaY., OkamuraT.What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population?J Hum Hypertens2005; 19: 165–172.
90.
KjaerA., AppelJ., HildebrandtP., PetersenC.L.Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects.Eur J Heart Fail2004; 6: 29–39.
91.
MottramP.M., HaluskaB.A., MarwickT.H.Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload.Am Heart J2004; 148: 365–370.
92.
MarguliesK.B., JafferS., PollackP.S., EnnisK.J.Physiological significance of early deceleration time prolongation in asymptomatic elderly subjects.J Card Fail1999; 5: 92–99.
93.
WilkinsM.A., SuX.L., PalayewM.D.The effects of posture change and continuous positive airway pressure on cardiac natriuretic peptides in congestive heart failure.Chest1995; 107: 909–915.
94.
McCulloughP.A., DucP., OmlandT.B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.Am J Kidney Dis2003; 41: 571–579.
95.
DavisM., EspinerE., RichardsG.Plasma brain natriuretic peptide in assessment of acute dyspnoea.Lancet1994; 343: 440–444.
